Page last updated: 2024-11-07

4-succinimidyloxycarbonyl-alpha-methyl-alpha(2-pyridyldithio)toluene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID130706
SCHEMBL ID42875
MeSH IDM0162302

Synonyms (20)

Synonym
smpt
(2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate
112241-19-7
4-succinimidyloxycarbonyl-alpha-methyl-alpha(2-pyridyldithio)toluene
2,5-pyrrolidinedione, 1-((4-(1-(2-pyridinyldithio)ethyl)benzoyl)oxy)-
4-succinimidyloxycarbonyl-alpha-methyl-alpha-(2-pyridyldithio)toluene
SCHEMBL42875
smpt (4-succinimidyloxycarbonyl-alpha-methyl-alpha(2-pyridyldithio)toluene)
AKOS027257098
1-[(4-{1-[(pyridin-2-yl)disulfanyl]ethyl}benzoyl)oxy]pyrrolidine-2,5-dione
DTXSID70920701
4-succinimidyloxycarbonyl-alpha-methyl-alpha(2-pyridyldithio) toluene
4-succinimidyloxycarbonyl-|a-methyl-|a-(2-pyridyldithio)toluene
2,5-dioxopyrrolidin-1-yl 4-(1-(pyridin-2-yldisulfaneyl)ethyl)benzoate
A910297
F82456
MS-26445
HY-126405
CS-0103518
PD171015

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic studies showed that the terminal-phase plasma half-life of ZME-RG was similar to that of ZME itself (42 h vs 50 h) and almost threefold higher than that of ZME-NG (11."( Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin.
Cheung, LH; Marks, JW; Rosenblum, MG, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (9.09)18.7374
1990's6 (54.55)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's4 (36.36)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.45 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index5.09 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]